Back to search
Invasive Pulmonary Aspergillosis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Invasive Pulmonary Aspergillosis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Invasive Pulmonary Aspergillosis trials you may qualify forTo evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.
Aspergillus fumigatus PCR is currently used in conjunction with serum galactomannan to support the diagnosis of invasive aspergillosis or for monitoring at-risk…
This trial is aimed to study the immunological and pathological characteristics of influenza versus non-influenza severe community-acquired pneumonia patients i…
Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and m…
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (P…
The last decade has seen a significant increase in secondary Aspergillus infections, not only due to primary hypersensitivity, and immunodeficiency based on onc…
To assess the safety and efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA
A prospective multi-center observational study to assess the incidence of influenza-associated pulmonary aspergillosis (IAPA) in ICU patients and to identify ho…
Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection of the respiratory system, caused by a specific fungus called Aspergillus species.…